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More than 95% of acute promyelocytic leukemia (APL; FAB-M3) 
cases are associated with the recurrent t(15;17)(q22:q11) translo-
cation, which results in the expression of a fusion transcript pro-
myelocytic leukemia–retinoic acid receptor α (PML-RARA), incon-
sistent expression of a reciprocal fusion product (RARA-PML), 
and haploinsufficiency for both PML and RARA (1, 2). Although 
APL has served as an important model disease for understand-
ing leukemogenic pathways directed by a specific translocation, 
the precise mechanisms by which t(15;17) initiates leukemia 
remain unknown.
Several mouse models have been used to study the mechanisms 
by which PML-RARA causes transformation (reviewed in refs. 3, 4). 
These models have used viral transduction, transgenic, and 
knockin strategies; regulatory sequences from the MRP8 gene (also 
known as S100 calcium binding protein A8 [S100A8]) and human 
and murine cathepsin G (CTSG and Ctsg, respectively) genes have 
been used to direct the expression of PML-RARA to the myeloid 
compartment (5–8), where can cause a myeloproliferative disease 
and APL after a long latent period.
However, there are many issues with existing mouse models of 
APL that must be addressed to fully understand how PML-RARA 
works. (a) The dose of PML-RARA is known to be important for 
AML penetrance, but no model to our knowledge has yet expressed 
PML-RARA from the endogenous Pml locus. This has not previous-
ly been attempted, since Pml is ubiquitously expressed, and since 
widespread expression of PML-RARA during development causes 
embryonic lethality (9, 10). (b) t(15;17) is a somatically acquired 
event, but all prior models have used constitutive PML-RARA 
expression, raising the possibility that hematopoietic cells may 
have adapted to tolerate PML-RARA expression during embryo-
genesis and/or early adult life. (c) Although Pml haploinsufficiency 
has been shown to contribute to APL pathogenesis, this has not 
been routinely integrated into mouse models (11).
To better define the initial effects of PML-RARA on hematopoiesis, 
we have developed a murine model (mPML-PRflox mice). We used 
homologous recombination to express PML-RARA under the con-
trol of the murine Pml locus and used Cre-Lox technology to pre-
vent PML-RARA expression prior to Cre recombination (to prevent 
embryonic lethality). This model recapitulates multiple elements 
of the pathologic t(15;17) translocation that have been absent in 
prior murine models of APL (i.e., Pml locus-appropriate expression 
of PML-RARA, Pml haploinsufficiency, and somatic acquisition of 
oncoprotein expression in adult animals).
In this report, we show that this model differs substantially from 
all previous ones and allows interrogation of initial PML-RARA 
effects on hematopoiesis after somatic acquisition of expression. 
When an ERT2-Cre cassette (driven by a chicken β-actin/CMV 
promoter/enhancer) is activated by tamoxifen in adult mice, 
mPML-PRflox is floxed and induces an inappropriate hemato-
poietic self-renewal program: floxed mPML-PRflox (designated 
mPML-fPR) bone marrow CFUs could be serially replated for 6 
or more weeks ex vivo and a progressive expansion of mPML-
fPR–positive hematopoietic cells occurred in vivo. Remarkably, 
this expansion occurred in the absence of concurrent myelo-
proliferation and was observed in both myeloid and lymphoid 
compartments after competitive transplantation. These studies 
show that PML-RARA alters self-renewal programs but does not 
alter homeostatic feedback mechanisms that control the size of 
the preleukemic myeloid compartment itself.
Results
PML and RARA expression in normal and leukemic human bone marrow 
cells. Because many translocations result in aberrant expression of 
at least one nearby gene (12), we evaluated the expression of both 
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PML and RARA across a wide range of AML patients with various 
FAB subtypes and in 5 normal volunteers, after flow sorting for 
CD34+, promyelocyte, and neutrophil (PMN) populations (13). We 
found no significant alteration in the expression of PML or RARA 
in patients with t(15;17) compared with those with non–FAB-M3 
AML (Figure 1). This suggests that t(15;17) does not influence 
hematopoiesis by grossly dysregulating the expression of either 
PML or RARA. These data also confirmed the prior observation 
that RARA expression is markedly upregulated during terminal 
myeloid maturation (Figure 1B and ref. 14).
Generation of mice with the mPML-PRflox allele. To more close-
ly recapitulate the effects of dose-appropriate expression and 
somatic acquisition of PML-RARA on hematopoiesis, we used 
homologous recombination to insert a loxP-PGKneo-stop-loxP-
PML-RARA cDNA into the murine Pml 5ʹ untranslated region 
(designated mPML-PRflox) of a C57BL/6-derived (B6-derived) ES 
cell line (B6-Blu), which was then used to generate B6 mice with 
this mutant allele (Figure 2A). Five stop codons positioned across 
all 3 reading frames were inserted downstream from the PGK-neo 
cassette to prevent expression of PML-RARA prior to Cre-mediated 
recombination. mPML-PRflox mice are viable and display normal 
Mendelian inheritance and normal peripheral blood cell counts 
(data not shown). The Cre-recombined allele expresses PML-RARA 
mRNA and protein and is referred to hereafter as mPML-fPR.
We first assessed the effect of the mPML-PRflox allele on Pml 
expression using Western blotting (Supplemental Figure 1A). 
As expected, we observed a decrease in Pml protein in mPML-
PRflox+/– spleen cells and a complete loss of Pml protein in mPML-
PRflox+/+ spleen cells. These data confirm that mPML-PRflox 
results in a null mutation in Pml and that heterozygosity creates 
haploinsufficiency for Pml.
We crossed mPML-PRflox mice (made in a B6 ES cell line and main-
tained in the B6 strain) with several different Cre-expressing mouse 
lines that were also made in or backcrossed to the B6 background. We 
first crossed mPML-PRflox mice to Mx-Cre mice but did not observe 
any doubly positive Mx-Cre+/– × mPML-PRflox+/– mice. Because Mx-Cre 
is expressed at low levels even without interferon activation and 
Pml is expressed widely during embryogenesis, we suspected that 
these mice died during embryogenesis because of Mx-Cre “leaki-
ness” (9, 15, 16). To confirm this result, we crossed male CMV-Cre+/– 
mice with female mPML-PRflox+/– mice. We observed 7 out of 
16 CMV-Cre–/– × mPML-PRflox+/– male pups but 0 out of 13 
CMV-Cre+/– × mPML-PRflox+/– female pups (CMV-Cre is X-linked, 
and the female pups are obligate Cre heterozygotes) (Figure 2B). 
We further evaluated 51 E13.5 embryos from a total of 6 litters of 
CMV-Cre+/– × mPML-PRflox+/– intercrosses. Of these, 26 embryos were 
CMV-Cre+/–, 16 embryos were mPML-PRflox+/–, and 0 embryos were 
CMV-Cre+/– × mPML-PRflox+/–. No resorbed embryos were observed in 
any of the 6 litters. This confirms that the floxed mPML-fPR allele 
causes early embryonic lethality when PML-RARA is widely expressed 
(consistent with prior observations that PML-RARA can cause cellu-
lar toxicity) (17–19) and provides strong evidence that PML-RARA is 
functional when it is activated by Cre-recombinase in this locus.
In contrast, Cre cassettes with more restricted expression pat-
terns could be successfully intercrossed; doubly heterozygous 
mice containing the LysM-Cre or the ERT2-Cre allele survived to 
adulthood with normal blood counts and without gross pheno-
types (LysM-Cre expression is limited to differentiated myeloid 
cells, and ERT2-Cre is active only after tamoxifen treatment) 
(20–22). Due to previously described cellular and embryonic tox-
icity from PML-RARA expression, we were surprised that ERT2-
Cre+/– × mPML-PRflox+/– mice tolerated i.p. tamoxifen administra-
tion without evidence of gross toxicity (17–19, 22).
PML-RARA mRNA could be detected using qRT-PCR in LysM-
Cre+/– × mPML-PRflox+/– spleen cells and also in ERT2-Cre+/– × 
mPML-PRflox+/– bone marrow cells after tamoxifen treatment 
(Supplemental Figure 1, B and C; supplemental material available 
online with this article; doi:10.1172/JCI42953DS1). We compared 
this expression to our previous model of APL, in which the same 
PML-RARA cDNA is expressed from the Ctsg locus using a knockin 
strategy (herein referred to as mCG-PR mice), which results in 
constitutive PML-RARA expression in hematopoietic progenitors, 
promyelocytes, and PMNs (peak expression is in promyelocytes) 
(7). The mPML-fPR allele yielded lower PML-RARA mRNA expres-
sion, consistent with the fact that the Pml gene is expressed at 
much lower levels than the Ctsg gene during normal hematopoiesis 
(Welch, et al., unpublished observations). However, PML-RARA 
mRNA was much more abundant in the leukemic spleen cells of a 
LysM-Cre+/– × mPML-PRflox+/– mouse, perhaps because virtually all 
cells in the sample contained an active mPML-fPR allele (Supple-
Figure 1
Expression profiling. (A and B) Expression array profile of (A) human 
PML and (B) human RARA in 111 patients with indicated FAB-AML 
and 5 flow-sorted normal controls. CD34, CD34+ bone marrow cells; 
Pros, promyelocytes. Individual data points represent results from indi-
vidual patients. Horizontal bars are the median value.
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mental Figure 1C). We also detected PML-RARA protein in this 
leukemia sample, although we were unable to detect PML-RARA 
protein in bone marrow, spleen, or CFU-granulocyte/CFU-macro-
phage (CFU-G/CFU-M) cells from healthy 8-week-old mPML-fPR 
or mCG-PR mice (Supplemental Figure 1D and data not shown).
PML-RARA activity causes a microstippled pattern of native Pml 
protein in the nucleus (17). We observed this pattern of Pml nucle-
ar localization in mCG-PR+/– and LysM-Cre+/– × mPML-PRflox+/– 
splenic PMNs but not in wild-type or mPML-PRflox+/– spleen PMNs 
(Supplemental Figure 1E). After tamoxifen treatment, we also 
observed microstippling of nuclear Pml in ERT2-Cre+/– × mPML-
PRflox+/– spleen PMNs (Supplemental Figure 1E).
Collectively, these data show that the mPML-fPR allele results in 
Pml haploinsufficiency, that PML-RARA is expressed after exposure 
to Cre recombinase, and that PML-RARA has the expected effects 
on cellular functions.
Titrating floxing in vivo. Consistent with prior studies by Hayashi 
et al., ERT2-Cre activity resulted in dose-dependent floxing of the 
LoxP-flanked Neo cassette (22). After 5 doses of tamoxifen at 4 mg 
per dose i.p., we observed approximately 20% mPML-fPR alleles in a 
wide range of tissues by Southern blotting (data not shown). Because 
large amounts of DNA are required for this technique, we developed 
a qPCR-based assay, using primers that span the LoxP Neo cassette 
(“Flox” primer pair amplified the floxed locus only) or that span 
the first LoxP site (“Neo” primer pair amplified the native, unfloxed 
locus only) (Figure 2A and Supplemental Figure 2A). Amplifica-
tion of flox and neo primer pairs was normalized to amplification 
across the PML-RARA junction (“PR” primer pair amplified the 
mPML-PRflox allele). By titrating genomic DNA from mPML-fPR 
and mPML-PRflox+/– spleen cells we could calculate the percentage of 
floxed alleles within a population (Supplemental Figure 2A). Ampli-
fication of a genomic DNA mixture containing a population of 10% 
or 90% mPML-fPR alleles yielded consistent results across multiple 
experiments (Supplemental Figure 2B). These samples were ampli-
fied during each of the subsequent experiments and were used to 
calibrate floxing efficiency. Using this approach, we confirmed a 
dose-dependent increase in the mPML-fPR allele in bone marrow 
from ERT2-Cre+/– × mPML-PRflox+/– mice: after 1, 5, and 10 doses of 
4 mg i.p. tamoxifen, we observed approximately 10%, 30%, and 95% 
floxed alleles, respectively (Supplemental Figure 2C).
Early effects of PML-RARA on hematopoiesis. Despite the significant 
embryonic toxicity observed with the mPML-PRflox transgene 
when crossed with Mx-Cre or CMV-Cre, we observed very little 
acute hematopoietic toxicity in ERT2-Cre+/– × mPML-PRflox+/– 
mice after tamoxifen treatment. After 10 doses of i.p. tamoxifen 
(4 mg each, administered in twice weekly doses), we evaluated 
peripheral blood counts and bone marrow progenitor compart-
ments in 4 ERT2-Cre+/– × mPML-PRflox+/– mice (these mice all 
achieved more than 95% floxing in their bone marrow cells) and 
their littermate controls. Tamoxifen treatment did not acutely 
alter total peripheral blood white blood cell numbers, hemoglo-
bin levels, platelets, or the percentage of lymphocytes, granulo-
cytes, or monocytes (data not shown). Evaluation of bone mar-
row cells revealed a small decrease in Kit+Lin–Sca+ (KLS) cells in 
mPML-fPR mice (1.3% vs. 2.5% of lineage-negative cells; P = 0.09) 
but no other significant changes in progenitor populations 
(Figure 3B). Bone marrow cells were cultured in methylcellulose 
containing IL-3, IL-6, and SCF, and CFUs were assessed after 1 
week. mPML-fPR did not significantly alter total CFUs or the 
immunophenotype of these cells after myeloid differentiation 
(Figure 3, C and D). Short pulses of 6 mg tamoxifen (given i.p. 
every other day for 10 days) resulted in 75% floxing in bone mar-
row and spleen cells and a nonsignificant trend toward decreased 
CFUs and CFU-Ms (Supplemental Figure 3, A and B). Exposure 
to 4-hydroxytamoxifen in vitro caused a modest decrease in total 
CFUs and CFU-Ms, but there was no change in total CFUs arising 
in methylcellulose with G-CSF alone (Figure 3E and Supplemen-
tal Figure 3C). Surprisingly, these data suggest that acute expo-
sure of hematopoietic cells to PML-RARA (at a dose governed by 
the Pml locus) is minimally toxic to early progenitor populations, 
leaving the hematopoietic compartments largely unperturbed.
However, Cre-dependent activation of mPML-PRflox resulted 
in dysregulation of hematopoietic self-renewal. After 10 doses 
of tamoxifen (4 mg i.p. twice weekly), bone marrow cells from 
ERT2-Cre+/– × mPML-PRflox+/– mice could be serially passaged 
for more than 6 weeks (Figure 4B). The self-renewal phenotype 
was completely dependent on floxing, since the floxed allele 
frequency increased during replating and represented 100% of 
the alleles after 4 weeks of culture (Figure 4C). Outgrowth of 
the mPML-fPR allele occurred whether the starting bone mar-
Figure 2
mPML-PRflox targeting strategy and the 
result of intercrosses with CMV-Cre, LysM-
Cre, and ERT2-Cre mice. (A) Targeting 
strategy. Rectangles represent exons. (B) 
The results of intercrosses with mPML-
PRflox × CMV-Cre, (C) mPML-PRflox × 
LysM-Cre, and (D) mPML-PRflox × ERT2-
Cre mice are shown, with details about 
resulting pups.
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row contained 40% or 95% floxed alleles (Figure 4C). LysM-Cre 
did not recapitulate the replating phenotype, nor did it result 
in an expansion of the mPML-fPR allele during serial passaging 
(Figure 4, B and C). The differences observed between floxing 
induced by ERT2-Cre (active in diverse tissues during tamoxi-
fen therapy and in early hematopoietic stem cells) (23) versus 
that induced by LysM-Cre (active predominantly in late myeloid 
cells) (21) suggest that PML-RARA expression in late myeloid 
cells cannot reprogram these cells to self-renew.
In vivo effects of PML-RARA on hematopoiesis. To define the effects 
of mPML-fPR on hematopoiesis, we generated a tumor watch 
consisting of LysM-Cre+/– × mPML-PRflox+/– mice (n = 54) from 2 
Figure 3
mPML-fPR does not grossly alter bone marrow progenitor populations, CFUs, or ex vivo myeloid differentiation. (A) Schema showing that mice 
were treated with 10 doses of tamoxifen (4 mg i.p. twice weekly for 5 weeks) and analyzed 2 weeks later. (B) mPML-fPR modestly decreased the 
percentage of Lin–cKit+Sca+ (KLS) cells but not the percentage of Lin–cKit+Sca–CD16/32+CD34+ (GMP), Lin–cKit+Sca–CD16/32–CD34+ (CMP), 
or Lin–cKit+Sca–CD16/32–CD34– (MEP) cells. KLS is expressed as the percentage of Lin– cells; the others are expressed as the percentage of 
Lin–cKit+Sca– cells. Results are from 4 independent mice in each genotype. Horizontal bars are the median value. (C) mPML-fPR did not alter 
the number of CFUs in the bone marrow cells when grown for 7 days in methylcellulose containing IL-3, IL-6, and SCF (average ± SD). (D) 
mPML-fPR did not alter the immunophenotype of cells maturing during the methylcellulose culture in C. After 1 week in culture, cells were col-
lected from methylcellulose, washed, and stained as indicated. Representative results are from 2 experiments (average ± SD). Horizontal bars 
are the median value. (E) Acute exposure of ERT2-Cre+/– × mPML-PRflox+/– bone marrow cells to 4-hydroxytamoxifen (4-OH tam) (0.1 M or 1 M) 
modestly decreased the number of CFU-Ms and total CFUs. Bone marrow cells from mice without prior tamoxifen exposure were harvested and 
plated in methylcellulose, as above, containing increasing doses of 4-hydroxytamoxifen (average ± SD).
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founder mPML-PRflox lines and their littermate controls. After 
18 months of observation, we observed leukemia in only 1 LysM-
Cre+/– × mPML-PRflox+/– mouse (on day 481; Figure 5, A and B). 
Leukemic spleen cells expressed a primitive myeloid phenotype: 
cKit+Sca+CD34–CD16+Gr1dim. Analysis of this mouse identified 
90% and 95% mPML-fPR alleles in the peripheral blood and spleen 
cells, respectively. Interestingly, this mouse presented with a white 
blood cell count of 3,600 cells/μl and only modest splenomegaly 
(460 mg spleen weight). These spleen cells reconstituted leukemia 
in 5 adoptively transferred B6 mice, whose leukemic spleens con-
tained 100% floxed alleles (Figure 5, C–E).
Unexpectedly, the peripheral blood and spleen cells at 18 months 
in nonleukemic mice demonstrated no consistent expansion of a 
floxed population or evidence of myeloproliferation (Figure 5, A, 
F, and G). Analysis of 5 mPML-PRflox+/– mice at 18 months showed 
no evidence of the floxed allele in the absence of Cre recombinase 
(data not shown). Regardless, these data confirm that the mPML-
fPR transgene, activated in the LysM cell population, is capable of 
causing myeloid leukemia, albeit rarely.
In contrast, after limited exposure to tamoxifen in ERT2-Cre+/– 
mice, we observed that mPML-fPR caused a competitive advantage 
within hematopoietic cells in vivo. We treated 2 cohorts of mice 
(comprised of mice from 2 different founder mPML-PRflox lines 
and their littermate controls) with 1 (n = 6) or 5 (n = 4) doses of 
tamoxifen (4 mg i.p. twice weekly) and serially assessed the percent-
age of mPML-fPR alleles within the peripheral blood. Acquisition 
of the mPML-fPR allele did not alter peripheral blood counts dur-
ing 6 months of evaluation (Figure 6B and data not shown). How-
ever, we observed a marked increase in the percentage of peripheral 
blood mPML-fPR alleles over this same time period, regardless of 
the initial efficacy of floxing (Figure 6, C and D). A third cohort of 
ERT2-Cre+/– × mPML-PRflox+/– mice were followed without tamoxi-
fen treatment. Minimal floxing was detected in the peripheral 
blood of these mice, showing that leakiness of ERT2-Cre during 
adult life could not account for the expansion of mPML-fPR–posi-
tive cells after tamoxifen treatment (Figure 6D).
This competitive advantage continued through 18 months of age, 
when the mice were sacrificed. In bone marrow and spleen cells, the 
mPML-fPR allele comprised more than 95% of mPML-PRflox alleles 
in nearly all mice treated with 1 or 5 doses of tamoxifen (Figure 6E 
and data not shown). The relative percentage of bone marrow 
floxed alleles at 18 months correlated with prior observations in 
peripheral blood cells; the 2 mice that did not achieve more than 
95% floxed alleles in the bone marrow had the lowest percentage 
of peripheral blood floxed alleles from the beginning of the experi-
ment (mouse 11941 and 11933). Again, this expansion of mPML-
fPR–positive cells was not associated with myeloproliferation; the 
mice did not develop splenomegaly or exhibit increased myeloid 
cells in the bone marrow or spleen (Figure 6F and Supplemental 
Figure 4). One mouse (mouse 11401) developed a cutaneous infil-
trate reminiscent of the cutaneous MRP8-PML-RARA phenotype 
and was sacrificed on day 249 (data not shown) (6). One mouse 
(11930) developed splenomegaly. This was associated with a trans-
plantable leukemia that appeared unrelated to mPML-fPR; bone 
marrow and spleen cells contained only 10% floxed alleles and did 
not contain detectable amounts of PML-RARA protein (Figure 6E, 
Figure 4
mPML-fPR leads to inappropriate ex vivo self-renewal of bone marrow CFUs. (A) Experiment schema showing that ERT2-Cre+/– × mPML-
PRflox+/– mice and littermate controls were treated with tamoxifen (4 mg i.p. twice weekly for 10 doses). Bone marrow cells were plated in meth-
ylcellulose containing IL-3, IL-6, and SCF. At 7-day intervals, colony numbers were counted and cells were harvested and replated as indicated. 
(B) mPML-PRflox leads to inappropriate self-renewal when intercrossed with ERT2-Cre but not LysM-Cre. Representative results are from 2 
experiments. Data points represent average and SD from 4 individual mice. (C) The mPML-fPR allele was associated with continued CFU activ-
ity in ERT2-Cre, but not LysM-Cre, bone marrow. The percentage of mPML-fPR alleles was assessed at each time point in B using qPCR. Data 
points represent results from individual mice. Horizontal bars are the median value.
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Supplemental Figure 1D, and data not shown). These data con-
firm that mPML-fPR provides a competitive advantage in hemato-
poietic cells in vivo as well as in vitro. Unlike prior models of APL 
(but similar to human APL), the competitive advantage of mPML-
fPR was not associated with myeloproliferation, and homeostatic 
feedback regulation of myeloid compartment size was preserved.
PML-RARA–dependent leukemia has not yet been observed in 
ERT2-Cre+/– × mPML-PRflox+/– mice. An additional 12 mice were 
treated with 5 doses of tamoxifen and were followed for 15 months. 
One mouse became ill with myelodysplastic-like disease character-
ized by pancytopenia, a normal spleen (150 mg), and an infiltrate 
of Gr1+cKit+CD11b+ cells (79%) in the bone marrow, consisting pre-
dominantly of differentiated PMNs with few blasts (data not shown). 
CD45.2+ cells engrafted 2 sublethally irradiated CD45.1 recipients 
but did not recapitulate the proband’s disease (data not shown).
To determine whether the self-renewal phenotype was related to 
alterations in cell cycle or apoptosis, we examined BrdU uptake 
in ERT2-Cre+/– × mPML-PRflox+/– cells, both in vitro and in vivo. 
We observed no difference in BrdU uptake after in vivo tamoxifen 
or after acute exposure to 4-hydroxytamoxifen in vitro. We exam-
ined unmanipulated total bone marrow cells and bone marrow 
cells grown ex vivo in liquid culture containing IL-3, IL-6, and SCF, 
liquid culture containing G-CSF and SCF, or methylcellulose 
plating experiments containing the IL-3, IL-6, and SCF (data not 
shown). We examined annexin V/propidium iodine staining under 
similar conditions and identified no differences in the frequency 
of apoptotic cells based on genotype or tamoxifen exposure (data 
not shown). This suggests that the self-renewal phenotype may 
occur either through non–cell cycle/apoptotic pathways or that 
only a small subset of cells may be affected.
To validate the self-renewal phenotype in vivo and to define the 
compartment affected by mPML-fPR, we performed both competi-
tive and noncompetitive transplantation experiments. Initial com-
petitive transplantation of bone marrow from ERT2-Cre+/– × mPML-
PRflox+/– mice treated with 10 doses of tamoxifen was confounded by 
an early engraftment defect and wide variability in subsequent com-
petitive expansion (Supplemental Figure 5A). We observed a simi-
lar engraftment defect in bone marrow cells from ERT2-Cre+/– mice 
treated with tamoxifen, suggesting that this phenotype was caused 
by Cre toxicity to stem cells, which has been observed by others, and 
may partially explain the decrease in KLS cells seen in Figure 3B (23). 
We also observed a consistent competitive advantage associated with 
Figure 5
Rare leukemia in LysM-Cre × mPML-PRflox mice. (A) A tumor watch of LysM-Cre+/– × mPML-PRflox+/– mice (n = 54) resulted in leukemic mouse 
(mouse 6317, founder line 51) with 90% and 95% peripheral blood and spleen mPML-fPR alleles, respectively. Nonleukemic mice were evalu-
ated at 18 months and showed little evidence of expanded mPML-fPR alleles in either peripheral blood or spleen. (B) Spleen cell cytomorphology 
from mouse 6317, stained with Wright-Giemsa (original magnification, ×1,000). (C–E) Spleen cells from mouse 6317 were transplanted into non-
irradiated B6 mice (n = 5). In 6 weeks all mice were moribund, with (C) elevated white blood cell counts and (D) splenomegaly. (E) qPCR evalu-
ation of the spleen cells in moribund secondary recipients revealed 100% mPML-fPR. (F and G) Analysis of LysM-Cre+/– × mPML-PRflox+/– mice 
and littermate controls at 18 months revealed normal (F) white blood cell and (G) spleen sizes, with rare evidence of splenomegaly in LysM-Cre+/– 
mice, regardless of mPML-PRflox genotype. Data points represent results from individual mice. Horizontal bars are the median value.
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Pml haploinsufficiency in mPML-PRflox+/– bone marrow in both the 
granulocyte and lymphocyte compartments, consistent with prior 
observations that Pml haploinsufficiency shortens mCG-PR leuke-
mic latency (Supplemental Figure 5C, ref. 11, and data not shown).
We observed a competitive expansion of ERT2-Cre+/– × mPML-
PRflox+/– bone marrow cells after competitive and noncompetitive 
transplantation when donor bone marrow was transplanted prior 
to tamoxifen exposure (Figure 7). After confirming engraftment of 
competitor and donor cells, we administered 5 doses of tamoxifen 
(posttransplant recipients tolerated i.p. tamoxifen poorly, and we 
administered the drug by gavage). During 16 weeks of follow-up, 
we observed a consistent expansion of donor CD45.2+ peripheral 
blood cells in ERT2-Cre+/– × mPML-PRflox+/– recipients but not in 
ERT2-Cre+/– recipients (Figure 7, A and B). Similarly, after noncom-
petitive transplantation of total bone marrow from ERT2-Cre+/– × 
mPML-PRflox+/– donors, we observed a consistent expansion of 
cells with mPML-fPR alleles (Figure 7C). More robust expansion 
of PML-RARA cells in noncompetitive transplants compared with 
that in competitive transplants is partly explained by the fact that 
only a portion (~40%) of the CD45.2+ donor cells were floxed in the 
competitive studies (Figure 7, A and C, and data not shown).
Competitive expansion occurred across multiple hematopoietic 
lineages, suggesting that mPML-fPR affects a stem cell compart-
ment with multilineage potential (Supplemental Figure 6, A–D). As 
expected, we observed initial peripheralization of donor Gr1+ and 
Nk1.1+ cells from both ERT2-Cre+/– × mPML-PRflox+/– and ERT2-
Cre+/– donor cells, while peripheralization of CD19+ and CD3+ 
donor cells occurred more slowly (Supplemental Figure 6). After 
Figure 6
Expansion of mPML-fPR alleles after pulsed tamoxifen. (A) Experimental schema showing ERT2-Cre+/– × mPML-PRflox+/– mice and mPML-
PRflox+/– littermate controls were treated with 0, 1, or 5 doses of tamoxifen (4 mg i.p.). (B) mPML-fPR did not alter peripheral blood counts at 
6 months. NE, neutrophil; Ly, lymphocytes; Mo, monocytes; Eo, eosinophils; Hgb, hemoglobin; Plt, platelet. (C and D) After the initial pulse of 
tamoxifen, the percentage of mPML-fPR alleles in peripheral blood increased and was measured using qPCR at indicated time points. Numbers 
next to colored dots indicate specific mice. (E) At 18 months, the percentage of mPML-fPR alleles was assessed in bone marrow cells. (F) 
Expansion of mPML-fPR alleles was not associated with splenomegaly. Data represent results from individual mice at indicated time points. 
Horizontal bars are the median value.
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tamoxifen, we observed expansion of ERT2-Cre+/– × mPML-PRflox+/– 
donor cells within CD19+, Nk1.1+, and CD3+ lymphoid compart-
ments but no expansion of ERT2-Cre+/– donor cells (Supplemental 
Figure 6, B–D and F–H). By 14 weeks after transplant, the percent-
age of donor ERT2-Cre+/– cells declined in Gr1+ myeloid cells and 
remained constant with respect to the percentage of total donor 
cells in the peripheral blood at 6 weeks (Supplemental Figure 6E). 
In contrast, the percentage of Gr1+ ERT2-Cre+/– × mPML-PRflox+/– 
donor cells remained significantly higher than the percentage of 
total donor cells in the peripheral blood at 6 weeks (Supplemental 
Figure 6A). As before, expansion of mPML-fPR–positive cells was 
not associated with myeloproliferation; recipient mice maintained 
normal CBCs and peripheral blood differential counts through-
out the experiment (data not shown). These data provide further 
evidence that PML-RARA results in competitive expansion across 
multiple hematopoietic lineages, without disturbing the homeo-
static regulation of myeloid or lymphoid compartments.
Discussion
PML-RARA expression has been shown to lead to leukemia in mul-
tiple prior mouse models (reviewed in refs. 3, 4). This leukemia is 
typically associated with antecedent myeloproliferation (increased 
promyelocytes and CFUs), requires cooperating progression muta-
tions, and generally presents with high white blood cell counts (7, 
8, 24, 25). Because human APL is characterized by low white blood 
cell counts and an acute onset without antecedent myeloprolif-
eration (1), we sought to more accurately model human APL by 
placing PML-RARA under the regulatory control of the Pml locus, 
in the setting of somatic acquisition of expression and Pml hap-
loinsufficiency. Our observations that PML and RARA are not 
grossly dysregulated in t(15;17) human leukemic bone marrow 
samples suggest that the translocation does not dramatically alter 
the expression of either gene and that accurate, somatic expression 
of PML-RARA is likely to be important.
Our data show that adult acquisition of hematopoietic PML-RARA 
expression leads to a competitive advantage that allows PML-RARA– 
expressing cells to expand more efficiently than their wild-type 
counterparts both in vitro and in vivo. However, this expansion is 
not associated with evidence of myeloproliferation or dysregula-
tion of hematopoietic homeostasis (mice had normal progenitor 
numbers, CFUs, and normal CBCs and differentials during follow-
up). However, LysM-Cre (which is predominantly active in mature 
PMNs and macrophages) (20) did not recapitulate this self-renewal 
phenotype, raising the possibility that PML-RARA cannot repro-
gram terminally differentiated myeloid cells to self-renew.
The in vivo self-renewal phenotype was recapitulated after com-
petitive and noncompetitive transplantation (i.e., it was cell auton-
omous), and it was associated with both lymphoid and myeloid 
expansion but normal CBCs and differential counts. Collectively, 
these experiments demonstrate that PML-RARA affects a multipo-
tent progenitor compartment. These results are supported by our 
recent findings in mCG-PR mice, in which we have demonstrated 
that PML-RARA is expressed and functional in the KLS compart-
ment (Welch et al., unpublished observations). Both results contra-
dict the current paradigm, which suggests that PML-RARA trans-
forms a committed myeloid precursor (i.e., a promyelocyte) by being 
expressed at that stage of development (26–29). This is clearly not 
the case. It will be important to determine whether the maturation 
arrest results from development-specific cooperating factors (i.e., 
neutrophil elastase [ELANE]) or from cooperating mutations that 
display myeloid selectivity (i.e., mutations that occur in genes with 
myeloid-restricted expression) (17).
The leukemic penetrance of mPML-PRflox was very low in 
both LysM-Cre and ERT2-Cre intercrosses. This represents the 
sixth mouse model generated using the same PML-RARA cDNA. 
Each of these prior models have resulted in very different leuke-
mic penetrance, ranging from zero (cFes and CD11b) to nearly 
complete (mCG-PR and MRP8-PR), suggesting that the dose and 
timing of PML-RARA expression do significantly alter the suscep-
tibility of mice to leukemia development (Welch et al., unpub-
lished observations) (7–9, 30–32).
The model described here differs from the prior models in sev-
eral ways. Importantly, the expression of PML-RARA mRNA from 
the Pml locus is even lower than that measured from the mCG-PR 
Figure 7
Competitive and noncompetitive transplantation. Bone marrow from indicated donor mice (CD45.2) was transplanted with competitor bone 
marrow (CD45.1) into lethally irradiated recipients (CD45.1). After engraftment, recipients were treated with the indicated doses of tamoxifen 
(3 mg by gavage). At the indicated time points, peripheral blood (PB) was assessed by flow cytometry. (A) Assessment of ERT2-Cre+/– × 
mPML-PRflox+/– donor bone marrow cells. (B) Assessment of ERT2-Cre+/– donor bone marrow cells. (C) Assessment of ERT2-Cre+/– × mPML-
PRflox+/– donor bone marrow cells. Results represent average and SD from indicated numbers of mice in each cohort.
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mice, which is in turn much lower than the expression in hCG-PR 
transgenic animals. Consistent with this, we have recently found 
that the expression pattern of PML is very different from that of 
CTSG and MRP8 in both mice and humans; it is much lower with no 
dynamic induction during promyelocyte maturation (Welch et al., 
unpublished observations). Our group has previously shown that 
reduced dose levels of PML-RARA are associated with less neutro-
phil elastase–dependent myeloid toxicity (17). However, the dose 
of PML-RARA expression obtained in mCG-PR mice is still associ-
ated with myeloid proliferation, reminiscent of “rebound” after 
recovery from cytotoxic therapy. In contrast, after acute exposure 
to mPML-fPR, we observed essentially no hematologic toxicity 
and no evidence for myeloproliferation (normal progenitor num-
bers, normal differential counts, and normal CFU numbers). This 
decrease in toxicity and low leukemic penetrance makes this model 
an attractive system for testing mutational cooperativity. Studies 
are ongoing to assess the effects of JAK1 V658F (33) and radiation 
in these mice (34). Because antecedent myeloproliferation is not 
observed in APL patients, we suggest that the myeloproliferation 
and the increased penetrance observed in mCG-PR mice may par-
tially reflect the hematologic toxicity of overexpressed PML-RARA 
and the resultant early hematopoietic expansion that may occur 
as a consequence. These results suggest that PML-RARA, when 
expressed from the Pml locus, is not a “potent” oncogene and raise 
questions about the true penetrance of APL in people who sponta-
neously acquire t(15;17) in hematopoietic cells.
Finally, these data suggest a mechanism of initial t(15;17) activ-
ity. PML-RARA is necessary but not sufficient to cause leukemia in 
mice (in mouse models there is substantial leukemic latency that 
can be shortened by radiation, alkylator treatment, or coopera-
tion with other known leukemia progression mutations) (3, 35). 
However, human APL is characterized by an acute presentation, 
often in extremis (1). How does t(15;17) lead to an acute disease 
if it requires additional cooperating mutations? The results pre-
sented here and other data suggest that t(15;17) leads to a com-
petitive advantage that allows for expansion of t(15;17)-positive 
cells (36). This increases the probability of acquiring additional 
mutations in t(15;17)-positive cells, but it does not lead to myelo-
proliferation that could cause a chronic hematopoietic disorder. 
PML-RARA increases the number of self-renewing progenitors, 
but homeostatic feedback is lost only after critical secondary 
mutations are acquired. Further studies will be required to fully 
validate this model, but the data presented here have uncovered 
substantial differences from previous models with less physiologic 
designs. Once again, this study points out the importance of accu-
rately reproducing every aspect of oncogene activation to mimic 
the evolution of human cancers.
Methods
Expression array profiling. Human AML and normal hematopoietic cell 
expression profiling has been previously described (37). In brief, bone 
marrow aspirates were obtained from patients that gave informed con-
sent. RNA was prepared from the unfractionated snap-frozen cell pellets 
and profiled using the Affymetrix Human Genome U133 Plus 2.0 Array 
GeneChip microarrays (Affymetrix) at the Siteman Cancer Center Molecu-
lar and Genomic Analysis Core Facility (38).
Mice. The mPML-PRflox transgene was generated as described in Figure 2. 
PML-RARA cDNA was cloned downstream of a loxp-PGK-neo-stop-loxp 
cassette and then flanked by the 4.5-kb XbaI-EcoRI region upstream of Pml 
exon 1 and by the 4-kb EcoRI-ClaI fragment downstream of Pml exon 1. 
This construct was electroporated into B6-Blu ES cells made in the Siteman 
Cancer Center Embryonic Stem Cell Core (http://escore.im.wustl.edu/). 
Two independent targeted clones (numbered 51 and 109) were identified by 
Southern blotting and injected into B6 blastocysts. Chimeric male offspring 
were identified by LacZ activity in the peripheral blood, and the targeted 
locus in both clones was transmitted through the germline of B6 mice. Inter-
crosses were performed as described. Mx-Cre (B6.Cg-Tg[Mx1-cre]1Cgn/J), 
CMV-Cre (B6.C-Tg[CMV-cre]1Cgn/J), LysM-Cre (B6.129-Lyzstm1(cre)Ifo/J), and 
ERT2-Cre (B6.Cg-Tg[cre/Esr1]5Amc/J) mice were obtained from The Jack-
son Laboratory, and all were otherwise on a B6 background. Activation of 
ERT2-Cre was performed by i.p. injection or gavage of tamoxifen dissolved 
in sterile corn oil (Sigma-Aldrich) as previously described (22). In wild-type 
B6 mice, 6 mg i.p. tamoxifen proved to be dose limiting, and we thus typi-
cally administered 4 mg tamoxifen. Peripheral blood counts were accessed 
as indicated (Hemavet 950, Drew Scientific Group).
Competitive repopulation was performed by retro-orbital injection of 
1 × 106 total bone marrow cells into lethally irradiated Ly5.1 recipients 
(CD45.1) that received 1,100 cGy total body irradiation (Mark 1 Cesum137 
irradiator, JL Shepherd) 24 hours prior to transplantation.
The Washington University Institutional Review Board approved the 
collection and molecular characterization of bone marrow cells collected 
from AML patients and from normal subjects. The Washington University 
Animal Studies Committee approved all animal experiments.
Hematopoietic progenitor assay. After lysis of red blood cells (ACK buffer: 
0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA), bone marrow cells were 
counted using a hemocytometer and plated in duplicate in 1.1 ml of methyl-
cellulose medium containing IL-6, IL-3, and SCF (MethoCult M3534, Stem-
Cell Technologies) (36). Cells were plated at 8.3 × 103 cells/ml. Colonies 
with more than 30 cells were counted on day 7. Cells were collected in warm 
DMEM, washed, and counted. Cells were then replated at the same density. 
This process was repeated for 6 weeks or until colony formation failed.
Flow cytometry. After lysis of red blood cells, peripheral blood, bone marrow, 
or spleen cells were treated with anti-mouse CD16/32 (eBioscience, clone 93) 
and stained with the indicated combinations of the following antibodies: 
FITC-αGr1 (BD Pharmingen, clone RB6-8C5); PE-αCD11b (eBioscience, 
clone M1/70); PE-αCD115 (eBioscience, clone AFS98); FITC-αCD34 (BD 
Pharmingen, clone RAM34); FITC-NK1.1 (eBioscience, clone PK136); APC-
αcKit (eBioscience, clone 2B8); PE-αCD3 (BD Pharmingen, clone 145-2C11); 
PE-αCD19 (eBioscience, clone MB19-1); PE-αB220 (BD Pharmingen, clone 
RA3-6B2); biotin-αCD34 (eBioscience, clone RAM34); PercP-Cy5.5-αGr1 
(eBioscience, clone RB6-8C5); PerCP-Cy5.5-αCD45.2 (eBioscience, clone 
104); APC-αCD45.1 (eBioscience, clone A20); APC-αSca (eBioscience, clone 
D7); APC-Cy7-αCD117 (eBioscience, clone 2B8); or lineage cocktail (αCD3, 
CD3e), αCD8 (clone 53-6.7), αCD4 (clone L3T4), αCD19 (clone 1D3), 
αB220 (clone RA3-6B2), αGr1 (clone RB6-8C5), or αTerr-119 (clone Ly-76) 
(all PE-Cy7–conjugated antibodies, eBioscience). Analysis was performed 
using a FACScan (Beckman Coulter) or Reflection cell sorter (iCyt), and data 
analyzed using FlowJo, Excel (Microsoft), and Prism 5 (Graphpad).
Western blotting. Whole cell lysates were prepared from spleen cells and NB4 
cells in 2× sample buffer. Lysates from equal numbers of cells were separated 
on a 10% NuPAGE Bis-Tris gel (Invitrogen) and transferred onto Hybond C 
Extra nitrocellulose membrane (Amersham). The membrane was probed with 
an anti-Pml antibody (1:500; Millipore, clone 16.1-104), a polyclonal anti-
RARA antibody (a gift from Scott Kogan, UCSF, San Francisco, California, 
USA) or anti-αActin (1:1,000; Millipore). Immune complexes were revealed by 
a peroxidase-conjugated anti-mouse IgG (1:10,000; GE) or conjugated anti-
rabbit IgG (1:2,500; GE) and visualized by chemiluminescence (Pierce).
Immunofluorescence. Spleen cells were fixed in methanol at –20°C and 
then rehydrated in PBS. Staining was done with α-Pml (1:200; Millipore, 
clone 16.1-104), goat α-mouse IgG Alexa Fluor 488 (1:200; Invitrogen) in 
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2% goat serum, and Vectashield (H-1200, Vector Laboratories). Cells were 
visualized on a Microphot-SA with Digital Sight imaging (Nikon).
qRT-PCR. Bone marrow and spleen cells were prepared using TRIzol 
(Invitrogen). RNA was treated twice with Turbo DNAfree (Ambion). cDNA 
was prepared using Superscript (Invitrogen) and amplified using Quanti-
Tect SYBR Green (Qiagen) and 7300 Real Time PCR (Applied Biosystems) 
per manufacture specifications. Primers used were as follows: PML-RARA 
(ENF903 TCTTCCTGCCCAACAGCAA; ENR962 GCTTGTAGATGC-
GGGGTAGAG); Pml (mPML-F CAGCCATTGAGACCCAGAGCAG; 
mPML-R GCAAGGCTTGTAGATGCGGGGTAG); and Gapdh (GAP-F 
TGCACCACCAACTGCTTAG; GAP-R GGATGCAGGGATGATGTTC).
qPCR. The percentage of floxed alleles was determined after DNA extrac-
tion using a DNeasy Blood and Tissue Kit (Qiagen). Genomic DNA was 
sonicated at 50% for 30 seconds using a Branson Sonifier 450 (VWR Sci-
entific). Quantitative PCR was performed using QuantiTect SYBR Green 
(Qiagen) and a 7300 Real Time PCR (Applied Biosystems) per manufacturer 
specifications. Primers used were as follows: floxed (Floxed2F CCATTTCCC-
GCCTTCACCAGACCTA; Floxed2R GATCGGGATCGAATTCGGCTTG-
TACTGA); unfloxed (Floxed2F CCATTTCCCGCCTTCACCAGACCTA; 
Neo7R GTAGCGCCAAGTGCCCAGC); and PR control (ENF903 TCTTCCT-
GCCCAACAGCAA; ENR962 GCTTGTAGATGCGGGGTAGAG).
Statistics. Two-sided Student’s t test was calculated using Excel (Microsoft). 
P values < 0.05 were considered statistically significant. Results with signifi-
cant P values are indicated in the text and figures, and the corresponding 
P values are provided. Nonsignificant P values generally are not included 
in figures. Data presented with column graphs and error bars represent the 
average ± SD. Other data represents results from individual mice.
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